×
ARYx Therapeutics Total Assets 2010-2010 | ARYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ARYx Therapeutics total assets from 2010 to 2010. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
ARYx Therapeutics Total Assets 2010-2010 | ARYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ARYx Therapeutics total assets from 2010 to 2010. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$180.5B
Regeneron Pharmaceuticals (REGN)
$126.8B
Vertex Pharmaceuticals (VRTX)
$123.3B
Gilead Sciences (GILD)
$104.5B
Bristol Myers Squibb (BMY)
$99.4B
CSL (CSLLY)
$97.5B
GSK (GSK)
$86.3B
Alnylam Pharmaceuticals (ALNY)
$35.5B
Argenex SE (ARGX)
$32.1B
Biogen (BIIB)
$29.3B
BioNTech SE (BNTX)
$26.8B
Moderna (MRNA)
$26.1B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.6B
Exact Sciences (EXAS)
$13.1B
Vaxcyte (PCVX)
$13.1B
Insmed (INSM)
$12.9B
Incyte (INCY)
$12.9B
Bio-Techne Corp (TECH)
$12.7B
Sarepta Therapeutics (SRPT)
$12.1B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Exelixis (EXEL)
$7.7B